Thyroid Function Test Market to Set Phenomenal Growth by 2027

Page 1

The global thyroid function test market was valued at approximately US$ 1.3 Bn in 2018. It is projected to register a cumulative annual growth rate (CAGR) of more than 5% from 2019 to 2027, according to a new report published by Transparency Market Research (TMR) titled ‘Thyroid Function Test Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027.’ Expansion of the health care industry, increase in health care expenditure, government initiatives, rise in product approvals, and increase in patient population are projected to augment the global market from 2019 to 2027. North America and Western Europe are likely to account for a dominant share of the global thyroid function test market, owing to advancements in healthcare and products and business expansion by various market leaders. Development of health care infrastructure and high medical expenditure by governments in emerging markets, such as China and India, are likely to boost the thyroid function test market in Asia Pacific at a CAGR of around 6.5% from 2019 to 2027. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=35750 Increasing incidence of thyroid gland disorders to propel market The global thyroid function test market is majorly driven by increasing incidence of thyroid disorders such as hypothyroidism and hyperthyroidism. Rise in the number of patients affected with autoimmune diseases (which is the major risk factor for thyroid disorder), such as Grave’s disease, is considered a major factor for consistent increase in incidence of thyroid disorder. Organizations such as the World Health Organization (WHO) and the American Association of Clinical Endocrinologists (AACE) have stated that thyroid disorders are rapidly increasing, and they demand novel and effective thyroid therapeutics for treatment. For instance, according to WHO estimates, thyroid disorders such as hypothyroidism, hyperthyroidism, and goiter are common conditions affecting more than 750 million people globally. The Journal of Clinical Endocrinology and Metabolism also estimated that thyroid dysfunction (i.e. hypothyroidism) is the leading endocrine disorder, and accounts for around 30% to 40% of the total endocrine patients. Thus, increase in the prevalence of thyroid disorders drives the demand for thyroid function tests such as TSH, T3, and T4. Additionally, prevalence of these disorders is increasing at a consistent pace in developed countries. This is anticipated to boost sales of thyroid therapeutics. According to the Endocrine Society, around 140 hypothyroidism and 10 hyperthyroidism cases are reported among every 1,000 individuals in the U.S. each year. These factors are expected to fuel the market in the near future. Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php? flag=CR&rep_id=35750 Rise in obese, diabetic, and cardiovascular patients Obese, diabetic, and cardiovascular patients are at a higher risk of developing hypothyroidism and hyperthyroidism. Rise in obese, diabetic, and cardiovascular patients is likely to increase the incidence of thyroid disorders, leading to increase in thyroid function test. Several statistics and clinical studies indicate that thyroid abnormalities are more common in obese, diabetic, and cardiovascular patients. For example, in July 2013, the Journal of Clinical Endocrinology and Metabolism published a cross sectional


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.